A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
19 06 2019
19 06 2019
Historique:
received:
16
07
2018
revised:
18
12
2018
accepted:
02
05
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
1
7
2020
Statut:
ppublish
Résumé
Advanced ovarian cancer is frequently treated with combination chemotherapy, but high recurrence rates show the need for therapies that can produce durable responses and extend overall survival. Bispecific antibodies that interact with tumor antigens on cancer cells and activating receptors on immune cells offer an innovative immunotherapy approach. Here, we describe a human bispecific antibody (REGN4018) that binds both Mucin 16 (MUC16), a glycoprotein that is highly expressed on ovarian cancer cells, and CD3, thus bridging MUC16-expressing cells with CD3
Identifiants
pubmed: 31217340
pii: 11/497/eaau7534
doi: 10.1126/scitranslmed.aau7534
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
CA-125 Antigen
0
Immunoglobulin G
0
MUC16 protein, human
0
Membrane Proteins
0
CD13 Antigens
EC 3.4.11.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.